CDKN2A and oropharynx cancer: Several studies have shown that patients with HPV(+) oropharyngeal cancer, as identified using PCR, in situ hybridization, or immunohistochemistry for p16 in tumor tissue, have significantly improved overall survival compared with patients with HPV(−) oropharyngeal cancer [2,23,24].